10 High Growth Healthcare Stocks to Invest in Now

2. BeiGene, Ltd. (NASDAQ:BGNE)

Revenue Growth: 122.61% 

BeiGene, Ltd. (NASDAQ:BGNE) is a global oncology company that discovers, develops, and commercializes innovative cancer medicines. The company focuses on creating affordable and accessible treatments for various types of cancer, including solid tumors and blood cancers.

BeiGene, Ltd. (NASDAQ:BGNE) is strengthening its global oncology leadership with its R&D and clinical advantages. BRUKINSA leads new patient starts in frontline and relapsed/refractory CLL in the US, along with other B-cell malignancies. The company is also expanding access to its PD-1 inhibitor, TEVIMBRA, for solid tumors globally and building commercial capabilities for its growing pipeline of cancer therapies.

The corporation has been establishing the groundwork for future franchises in the areas of gastrointestinal, lung, and breast cancers using three signature platform technologies: antibody-drug conjugates, protein degraders, and multi-specific antibodies. Additionally, the commercial capabilities were strengthened through strategic alliances with major players in the sector like Novartis and Amgen. Its revenues in the third quarter of 2024 were over $1 billion, whereas those in the same period in 2023 were $781 million. This rise was mostly caused by an 87% increase in BRUKINSA product sales in the US and a 217% increase in sales in Europe.

Baird Asset Management controlled Chautauqua Capital Management, a boutique investment firm, released the third-quarter 2024 investor letter. Here is what the fund said:

“BeiGene, Ltd. (NASDAQ:BGNE) is expected to have excellent top- and bottom-line growth over the next several years, driven by Brukinsa, their best-in-class product in several hematology cancers, with a global market size of approximately $9 billion in 2023. Even though the company is truly global in nature, incorporated in Switzerland and headquartered in Basal, Beijing, and Cambridge, MA, its valuation was depressed due to negative sentiment towards China, as it does have a large R&D and sales team in China. The recent rally in China stocks has somewhat reduced the extreme pessimism seen earlier in the year.”